PharmaLytica 2021 Hyderabad review.

Aurobindo, Kinvan, K'taka Antibiotics qualified for PLI scheme to promote domestic manufacturing of drugs

Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid



22 January, 2021 Mumbai; Hyderabad based Aurobindo Pharma, Kinvan Pvt Ltd, Mumbai and public sector firm Karnataka Antibiotics and Pharmaceuticals are the three companies announced by the central government that have qualified for financial support under the production linked incentive (PLI) scheme for promotion of domestic manufacturing of critical key starting materials (KSMs), drug intermediates and active pharmaceutical ingredients (APIs).

While Aurobindo Pharma has committed an investment of Rs 3,039 crore to set up production facilities for three eligible products, Kinvan will invest Rs 447.17 crore to build 300 MT capacity plant to produce Clavulanic Acid. Karnataka Antibiotics will set up 1,000 MT production capacity to produce 7-ACA (a chemical needed to produce cephalosporin antibiotics and intermediates) with an investment of Rs 275 crore. Aurobindo, through Lyfius Pharma, will set up a 15,000 MT capacity Penicillin G production facility and a 2,000 MT capacity facility for 7-ACA with an investment of Rs 1,392 crores and Rs 813 crore, respectively. Aurobindo has also committed to set up a 1,600 MT capacity Erythromycin Thiocyanate (TIOC) manufacturing plant at a cost of Rs 834 crore through its partner Qule Pharma.

Announcing the decision, chemicals ministry said the setting up of these plants will lead to total committed investment of Rs 3,761 crore by the companies and employment generation of about 3,825. The commercial production is projected to commence from April 1, 2023 and the disbursal of production linked incentive by the government over the six years period would be up to a maximum of Rs 3,600 crore. Setting of these plants will make the country self-reliant to a large extent in respect of these bulk drugs, the ministry said.


×

This Website Uses Cookies for Google Analytics, to improve your experience and to show you personalized advertising. By using this website you agree to our COOKIES AND PRIVACY POLICY...Learn More